Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
57.7% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
26
users have liked this narrative
7
users have commented on this narrative
74
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
28.0% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
35
users have liked this narrative
6
users have commented on this narrative
96
users have followed this narrative
Updated
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
20.6% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Deutsche Pfandbriefbank
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
European CRE Troubles Will Hinder Loans Despite Modest Optimism
Key Takeaways Exposure to weak commercial real estate markets and shifts in office demand create structural risks, threatening asset quality and loan growth. Rising regulatory burdens and competition from alternative lenders could erode profitability and constrain efforts to improve cost efficiency and market share.
View narrative
€6.00
FV
9.3% undervalued
intrinsic discount
15.01%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Rio Tinto Group
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Aging Pilbara Assets And Rising Costs Will Erode Returns
Key Takeaways Heavy reliance on aging assets and regulatory pressures threaten Rio Tinto's production stability, growth prospects, and ability to replenish reserves. Rising costs, decarbonization challenges, and legacy reputational issues may compress margins and limit access to partnerships and capital.
View narrative
UK£39.90
FV
14.6% overvalued
intrinsic discount
-1.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
1 day ago
author updated this narrative
Indraprastha Gas
AN
AnalystLowTarget
Consensus Narrative from 30 Analysts
Declining CNG Demand In Delhi Will Erode Long-Term Market Position
Key Takeaways Rapid adoption of electric vehicles and renewables is eroding core CNG demand, shrinking IGL's addressable market and threatening long-term growth prospects. Structural overreliance on Delhi-NCR and rising competition amplify revenue concentration risks, margin pressure, and potential for stranded asset exposure.
View narrative
₹155.00
FV
30.4% overvalued
intrinsic discount
2.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Cegedim
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Legacy Challenges Will Test Healthcare Digitalization As Modest Opportunities Open
Key Takeaways Legacy IT reliance and underperformance in core divisions constrain growth, as newer digital competitors erode market share and hinder innovation. Limited international success and tightening regulatory demands restrict diversification, keeping growth dependent on mature home markets and pressuring profitability.
View narrative
€11.00
FV
2.7% undervalued
intrinsic discount
3.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Berry
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
California Exposure Will Strain Operations While Utah Gains Mitigate Risks
Key Takeaways Heavy reliance on California operations increases exposure to strict regulations, political risks, and future revenue uncertainty. Global shift toward renewables and ESG scrutiny pose structural threats to long-term demand, margins, and financial flexibility.
View narrative
US$3.50
FV
19.7% undervalued
intrinsic discount
0.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Spin Master
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Tariffs And Franchise Reliance Will Hinder Revenue Amid Digital Upside
Key Takeaways Heavy reliance on key franchises and licensed brands exposes Spin Master to significant revenue and gross margin volatility if any major IP underperforms. Higher input, operational, and promotional costs are pressuring margins, while global trade disruptions and demographic shifts challenge revenue growth and operational resilience.
View narrative
CA$23.93
FV
10.0% undervalued
intrinsic discount
1.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Prudent Advisory Services
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Digital Disruption Will Squeeze Revenues And Commissions In India
Key Takeaways Ongoing shifts toward passive investing and digital platforms threaten Prudent's revenue and margin growth by diminishing demand for traditional advisory services. Intensifying competition, regulatory pressures, and downward repricing will limit Prudent's profitability and make sustaining asset growth increasingly challenging.
View narrative
₹2.60k
FV
1.5% overvalued
intrinsic discount
18.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Rigel Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Regulatory Crackdowns And Pipeline Weakness Will Dominate Future Challenges
Key Takeaways Reliance on one-time revenue benefits, limited recurring income, and a narrow product portfolio creates significant risks for sustained earnings growth and long-term stability. Growing drug pricing pressures and shifting industry preferences away from small molecule therapies may reduce acquisition appeal, limit pricing power, and constrain future pipeline funding.
View narrative
US$23.00
FV
37.8% overvalued
intrinsic discount
-0.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
NATCO Pharma
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Unyielding US Controls And Heightened Competition Will Worsen Outlook
Key Takeaways Intensifying regulatory, pricing, and compliance pressures threaten profit margins and earnings, while exposure to US policy risks heightens uncertainty for future growth. Reliance on maturing generics, limited product diversification, and increasing competition may erode market share and make sustained revenue growth structurally challenging.
View narrative
₹710.00
FV
27.9% overvalued
intrinsic discount
-16.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies